Evidence map›Paper›PMID 39664181›Full record

ArticleFrontiers in oncology2024

Superior survival benefits of triple combination immunotherapy compared to standard chemotherapy as second-line treatment for advanced biliary tract cancer: a retrospective analysis.

Peipei Shang, Heming Xu, Tianmei Zeng, Cheng Lou, Wei Wei, Guang Yang, Zhuo Cheng, Xiaowen Cui, Weipeng Hong, Weidong Shen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Peipei Shang *Eastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Heming Xu *Eastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Tianmei ZengEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Cheng LouEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Wei WeiEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Guang YangEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Zhuo ChengEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Xiaowen CuiEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.
Weipeng HongMedical Department, Oyeah Biotech, Shanghai, China.
Weidong ShenMedical Department, Oyeah Biotech, Shanghai, China.
Zhicong LianDepartment of Marketing, Singlera Genomic Ltd., Shanghai, China.
Zhengang YuanEastern Hepatobiliary Surgical Hospital, Naval Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Advanced biliary tract cancer (BTC) is associated with a poor prognosis and limited options for second-line treatment. The TOPAZ-1 and KEYNOTE-966 trials have demonstrated the benefits of combining immune checkpoint inhibitors (ICIs) with chemotherapy in treating BTC. However, the efficacy of FOLFOX as a second-line therapy is limited, highlighting the need for more effective treatment approaches. Methods: This retrospective study compared a triple regimen-comprising ICIs, tyrosine kinase inhibitors, and chemotherapy-to standard chemotherapy in patients with metastatic BTC who had progressed on first-line gemcitabine-based therapy. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), overall response rate (ORR), disease control rate (DCR), and safety. Results: Of the 121 patients, 86 received the triple regimen and 35 received standard chemotherapy. The triple regimen showed a significantly higher ORR (37.2% vs. 2.8%, p < 0.0001) and DCR (89.5% vs. 71.4%). The median PFS was 6 months for the triple regimen compared to 2.0 months for standard chemotherapy (HR 0.29, p < 0.0001). The median OS was 16.0 months for the triple regimen versus 6.0 months for standard chemotherapy (HR 0.35, p < 0.0001). Treatment-related adverse events were comparable between the groups. Conclusion: The triple combination of immunotherapy offers superior survival benefits compared to standard chemotherapy as a second-line treatment for advanced BTC, warranting further investigation for potential clinical adoption.

Indexed as

BTCcombination (combined) therapyimmunotherapyretrospective studiessecond-line therapy

Identifiers

PMID39664181
PMCPMC11632691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.